Vertex tightens CF focus as promising flu candidate out-licensed to Janssen
This article was originally published in Scrip
J&J subsidiary Janssen has agreed to pay $30m upfront to Vertex Pharmaceuticals for global development and commercialization rights to a novel influenza candidate with a mechanism of action distinct from neuraminidase inhibitors, the current standard of care for the treatment of flu.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.